Abstract
Diabetes mellitus, a condition marked by impaired glucose regulation, encompasses various subtypes, with type 1 and type 2 being the most prevalent. The global incidence of diabetes is rapidly increasing, with projections reaching 552 million by 2030. Insulin resistance, a compromised physiological response of target tissues to insulin stimulation, plays a crucial role in the pathogenesis of diabetes and its associated metabolic abnormalities. Pharmacological interventions, including insulin and hypoglycemic agents, aim to increase insulin secretion, enhance glucose uptake, and reduce gluconeogenesis. However, managing diabetes extends beyond glycemic control, as comorbid mental health conditions, such as dementia, eating disorders, anxiety disorders, and depression, can worsen the progression of diabetes. While no specific pharmacological agent has been approved for treating insulin resistance, various drug classes and lifestyle modifications have shown effectiveness in improving insulin sensitivity. A comprehensive approach combining pharmacotherapy and lifestyle changes is essential for optimal treatment outcomes and reducing the risk of diabetes-related complications. Systematic analysis of the complex mechanisms underlying insulin resistance will facilitate the identification of novel therapeutic targets and improve the management of the closely related metabolic syndrome
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
